Bristol Myers Squibb (CELG-RI) Short-term Investments (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Short-term Investments for 18 consecutive years, with $2.3 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Short-term Investments rose 133.57% year-over-year to $2.3 billion; the TTM figure through Jun 2026 stood at $2.3 billion (up 133.57% YoY), while the FY2025 annual figure was $464.0 million, down 9.55% from the prior year.
• Short-term Investments climbed to $2.3 billion in Q2 2026 per CELG-RI's latest filing, from $912.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $2.6 billion in Q1 2022 and bottomed at $130.0 million in Q4 2022.
• Historically, Short-term Investments has averaged $885.8 million across 5 years, with a median of $644.5 million in 2024.
• Annual changes were most pronounced in 2022 — Short-term Investments sank 95.65% — and 2023, when it surged 527.69%.
• Bristol Myers Squibb's Short-term Investments stood at $130.0 million in 2022, then soared by 527.69% to $816.0 million in 2023, then sank by 37.13% to $513.0 million in 2024, then decreased by 9.55% to $464.0 million in 2025, then surged by 405.39% to $2.3 billion in 2026.
• Business Quant data shows CELG-RI's Short-term Investments at $2.3 billion in Q2 2026, $912.0 million in Q1 2026, and $464.0 million in Q4 2025.